Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Low-Dose Chemotherapy for Newly Diagnosed Ph+ ALL
NCT02690922Phase 4
Key facts
- Status
- Unknown
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Countries
- 1
- Sponsor
- Tongji Hospital
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Drugs
- dasatinib
- Conditions
- Acute lymphoblastic leukemia, Philadelphia chromosome positive
01
Overview
Phase 4, open-label, single-arm trial of dasatinib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Tongji Hospital. Primary endpoint: Major Molecular Remission Rate at 115 days. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
ph+ ALL with dasatinib
Dasatinib + Low-dose Chemotherapy
03
Who it enrols
Adult patients (>=18 years) with newly diagnosed Philadelphia chromosome-positive ALL, normal organ function, and no CNS leukemia or other malignancies.
04
Endpoints
Primary
Major Molecular Remission Rate
Secondary
Time Needed to Achieve Major Molecular Remission
Beyond the preview
Go deeper on NCT02690922.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690922.